Novartis’s Bulto: Kisqali Is Blueprint For More Competitive US Launches

Novartis enjoyed exceptional growth in 2024, and its US leader, Victor Bulto, puts that down to greater R&D and commercial co-ordination paying off with drugs such as Kisqali in early breast cancer.